v3.25.1

Operating costs and other operating income | 12 Months Ended
--- | ---
Dec. 31, 2024
Operating costs and other operating income |
Operating costs and other operating income | 8. Operating costs and other operating income RESEARCH AND DEVELOPMENT EXPENSES The following table summarizes research and development expenses for the years ended December 31, 2024, 2023 and 2022. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended December 31,
​ |  | 2024 |  | 2023 |  | 2022
​ | ​ | ​ | (Euro, in thousands)
Personnel costs | ​ | € | (87,740) | ​ | € | (95,788) | ​ | € | (115,484)
Subcontracting | ​ | ​ | (160,076) | ​ | ​ | (82,997) | ​ | ​ | (61,192)
Disposables and lab fees and premises costs | ​ | ​ | (17,629) | ​ | ​ | (18,083) | ​ | ​ | (19,529)
Depreciation, amortization and impairment | ​ | ​ | (35,378) | ​ | ​ | (22,254) | ​ | ​ | (51,493)
Professional fees | ​ | ​ | (15,949) | ​ | ​ | (9,272) | ​ | ​ | (9,316)
Other operating expenses | ​ | ​ | (18,687) | ​ | ​ | (12,900) | ​ | ​ | (12,783)
Total R&D expenses | ​ | € | (335,459) | ​ | € | (241,294) | ​ | € | (269,797)
​ The table below summarizes our research and development expenses for the years ended December 31, 2024, 2023 and 2022, broken down by program. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended December 31,
​ |  | 2024 |  | 2023 |  | 2022
​ | ​ | ​ | (Euro, in thousands)
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Ziritaxestat program | ​ | € | — | ​ | € | — | ​ | € | (1,096)
SIKi program | ​ | ​ | (18,400) | ​ | ​ | (18,900) | ​ | ​ | (47,727)
TYK2 program on GLPG3667 | ​ | ​ | (34,965) | ​ | ​ | (31,289) | ​ | ​ | (24,467)
Cell therapy programs in oncology | ​ | ​ | (170,998) | ​ | ​ | (82,218) | ​ | ​ | (29,999)
Other discovery programs | ​ | ​ | (111,096) | ​ | ​ | (108,887) | ​ | ​ | (166,507)
Total R&D expenses | ​ | € | (335,459) | ​ | € | (241,294) | ​ | € | (269,797)
​ SALES AND MARKETING EXPENSES The following table summarizes the sales and marketing expenses for the years ended December 31, 2024, 2023 and 2022. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended December 31,
​ |  | 2024 |  | 2023 |  | 2022
​ | ​ | ​ | (Euro, in thousands)
Personnel costs | ​ | € | (6,561) | ​ | € | (2,997) | ​ | € | (1,693)
Depreciation and impairment | ​ | ​ | (4,475) | ​ | ​ | (113) | ​ | ​ | (59)
External outsourcing costs | ​ | ​ | (2,813) | ​ | ​ | (1,776) | ​ | ​ | (1,267)
Professional fees | ​ | ​ | (904) | ​ | ​ | (131) | ​ | ​ | (99)
Other operating expenses | ​ | ​ | (2,440) | ​ | ​ | (659) | ​ | ​ | (363)
Total sales and marketing expenses | ​ | € | (17,193) | ​ | € | (5,676) | ​ | € | (3,480)
​ GENERAL AND ADMINISTRATIVE EXPENSES The following table summarizes the general and administrative expenses for the years ended December 31, 2024, 2023 and 2022. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended December 31,
​ |  | 2024 |  | 2023 |  | 2022
​ | ​ | ​ | (Euro, in thousands)
Personnel costs | ​ | € | (52,642) | ​ | € | (66,098) | ​ | € | (76,536)
Depreciation and impairment | ​ | ​ | (8,697) | ​ | ​ | (15,978) | ​ | ​ | (8,529)
Legal and professional fees | ​ | ​ | (33,960) | ​ | ​ | (23,250) | ​ | ​ | (23,715)
Other operating expenses | ​ | ​ | (21,946) | ​ | ​ | (22,963) | ​ | ​ | (26,375)
Total general and administrative expenses | ​ | € | (117,245) | ​ | € | (128,289) | ​ | € | (135,155)
​ ​ OTHER OPERATING INCOME The following table summarizes other operating income for the years ended December 31, 2024, 2023 and 2022. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended December 31,
​ |  | 2024 |  | 2023 |  | 2022
​ | ​ | ​ | (Euro, in thousands)
Grant income | ​ | € | 2,035 | ​ | € | 6,618 | ​ | € | 1,873
R&D incentives income | ​ | ​ | 27,223 | ​ | ​ | 32,968 | ​ | ​ | 29,104
Other income | ​ | ​ | 11,515 | ​ | ​ | 7,686 | ​ | ​ | 5,150
Total other operating income | ​ | € | 40,773 | ​ | € | 47,272 | ​ | € | 36,127
​ ​ The grant income in 2024, 2023 and 2022 was fully related to grants from a Flemish agency and the Belgian government. In many cases these grant agreements carry clauses which require us to maintain a presence in the same region for a number of years and invest according to pre-agreed budgets. Grant income in 2023 also included a grant of €6.1 million from the National Institute for Health and Disability Insurance (2024: nil, 2022: nil). This grant aimed to incentivize innovative Belgian biotech companies who are performing research and development activities in order to identify new medicines. R&D incentives income was primarily composed of: ​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year ended December 31,
​ |  | 2024 |  | 2023 |  | 2022
​ | ​ | ​ | (Euro, in thousands)
Income from innovation incentive system in France | ​ | € | 2,056 | ​ | € | 5,881 | ​ | € | 11,075
Income from Belgian R&D incentives | ​ | ​ | 16,943 | ​ | ​ | 16,535 | ​ | ​ | 10,339
Tax rebates on payroll withholding taxes of R&D personnel (Belgium & the Netherlands) | ​ | ​ | 8,224 | ​ | ​ | 10,552 | ​ | ​ | 7,689
Total R&D incentives income | ​ | € | 27,223 | ​ | € | 32,968 | ​ | € | 29,104
​

X
- References No definition available. + Details
Name: | glpg_OperatingCostsAndOtherOperatingIncomeAbstract
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of other operating income or expense. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration